

REVIEW

Open Access



Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD)

Zhi Dong Zhou^{1,3*†}, Sushmitha Sathiyamoorthy^{1†}, Dario C. Angeles² and Eng King Tan^{1,2,3*}

Abstract

Mutations of F-box protein 7 (FBXO7) and Parkin, two proteins in ubiquitin-proteasome system (UPS), are both implicated in pathogenesis of dopamine (DA) neuron degeneration in Parkinson's disease (PD). Parkin is a HECT/RING hybrid ligase that physically receives ubiquitin on its catalytic centre and passes ubiquitin onto its substrates, whereas FBXO7 is an adaptor protein in Skp-Cullin-F-box (SCF) SCF^{FBXO7} ubiquitin E3 ligase complex to recognize substrates and mediate substrates ubiquitination by SCF^{FBXO7} E3 ligase. Here, we discuss the overlapping pathophysiologic mechanisms and clinical features linking Parkin and FBXO7 with autosomal recessive PD. Both proteins play an important role in neuroprotective mitophagy to clear away impaired mitochondria. Parkin can be recruited to impaired mitochondria whereas cellular stress can promote FBXO7 mitochondrial translocation. PD-linked FBXO7 can recruit Parkin into damaged mitochondria and facilitate its aggregation. WT FBXO7, but not PD-linked FBXO7 mutants can rescue DA neuron degeneration in Parkin null *Drosophila*. A better understanding of the common pathophysiologic mechanisms of these two proteins could unravel specific pathways for targeted therapy in PD.

Keywords: FBXO7, Mitochondria, Mitophagy, Parkin, Parkinson's disease, Protein aggregation, Proteotoxicity, Ubiquitin proteasome system

Background

Parkinson's disease (PD) is one of the most common neurodegenerative disorder characterized by chronic and progressive loss of dopaminergic neurons in substantia nigra pars compacta (SN). PD can affect about 2 % of the population above 65 years of age [1–3]. PD symptoms include rigidity, postural instability, tremor at rest and slowness or absence of voluntary movement, and even neuropsychiatric symptoms [4, 5]. The pathological hallmarks of PD include progressive degeneration of dopamine (DA) neurons in SN [5, 6] as well as accumulation of α -synuclein (α -syn) positive Lewy bodies in afflicted brain regions [7–9]. Although various hypotheses,

including oxidative stress [10], mitochondrial dysfunction [11, 12], impairment of the ubiquitin proteasome system (UPS) and defects in autophagy process [1, 4, 11], have been proposed to be implicated in progressive loss of DA neurons in PD, the exact mechanisms accounting for DA neuron demise in PD still remains to be elucidated [13].

Though most PD cases are late onset and may be classified as sporadic PD (SPD), gene mutations or variations can lead to early onset inherited familial PD (FPD) [3, 14]. Accumulative evidence from studies on FPD have significantly deepened our understanding of PD pathogenesis [15]. The recessive mutations in Parkin gene (PARK2) are associated with classic Levodopa responsive FPD [16]. However recessive gene mutations of FBXO7 (PARK15) are associated with juvenile onset Parkinsonism frequently accompanied with atypical features including dementia, dystonia, hyperreflexia and pyramidal signs [17, 18]. Here, we discuss the overlapping pathophysiologic mechanisms and clinical features linking Parkin and FBXO7 with autosomal recessive PD.

* Correspondence: zhidong_zhou@nni.com.sg; Tan.eng.king@sgh.com.sg

†Equal contributors

¹National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore

²Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore

Full list of author information is available at the end of the article

UPS dysfunction, proteotoxicity and PD pathogenesis

There is increasing evidence to suggest that dysfunction of UPS plays a major role in PD pathogenesis. The function of UPS is to target and degrade unneeded or damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. The UPS processes involve targeted conjugation of multiple ubiquitin molecules to protein substrates and subsequent degradation of polyubiquitin tagged proteins by proteasome [19]. The process will finally yield peptides of about seven to eight amino acids long, which can be further degraded into shorter amino acid fragments for new proteins synthesis [20]. It was reported that proteasome inhibition induced UPS impairment can result in accumulation of misfolded proteins and deleterious protein aggregates, contributing to neuronal dysfunction and demise [21]. The accumulation of misfolded and aggregated proteins induced toxicity is termed as proteotoxicity, which has been found to be implicated in pathogenesis of various human disorders, including carcinogenesis, neurodegenerative diseases, aging process, cardiovascular disorders, diabetes and many other human diseases [22–25]. Recent findings indicate that PD-linked FBXO7 mutations aggravate aggregation of FBXO7 proteins in mitochondria contributing to FBXO7-linked mitochondria proteotoxicity, which is implicated in FBXO7 mutation induced DA neuron degeneration in PD [26].

Impairment of UPS in PD pathogenesis was established with mutations of Parkin, a HECT/RING hybrid ubiquitin E3 ligase [27, 28], and other genetic forms of PD [20, 29]. The impairment of UPS functions is also implicated in DA neuron degeneration in SPD. The DA in DA neurons can be an endogenous deleterious factor to impair UPS function via irreversible conjugation of protein cysteine residues by highly reactive DA oxidation derived DA quinones [30, 31]. DA quinone is reported to covalently modifies Parkin in living dopaminergic cells, leading to Parkin insolubility and inactivation of its E3 ubiquitin ligase function [32]. These findings show vulnerabilities of Parkin and UPS to reactive DA quinone, suggesting a mechanism for DA quinone induced progressive UPS impairment and Parkin inhibition in dopaminergic neurons during aging and SPD [30–32].

FBXO7 and FBXO7-linked PARK15

The FBXO7 R378G mutation was first reported to be linked to early-onset Parkinsonian (PARK15) in 2008 [33]. In 2009 R498X and T22M FBXO7 mutations were subsequently identified to induce autosomal recessive, early-onset Parkinsonian-pyramidal syndrome [17, 33]. The PARK15 patients presented with Babinski signs and spastic weakness [18, 34, 35]. Parkinsonism with resting tremor, bradykinesia and postural instability developed

in later stages of some PARK15 patients [36]. Recently a new FBXO7 L34R mutation causing typical L-dopa-responsive Parkinsonism was reported in a Turkish family [37]. The L34R mutation is similar to T22M mutation, which is predicted to affect the UBL domain of FBXO7 isoform 1 protein and is associated with disturbed nuclear localization of FBXO7 protein [37]. Another heterozygous mutation (R481C) of FBXO7 was reported in an Italian family [38, 39]. As these patients also carried other genetic variants related to PD, the pathogenicity of R481C FBXO7 mutant still remains to be clarified [17, 18]. However a potential protective Y52C FBXO7 polymorphism is recently identified [40]. The molecular structure of FBXO7 protein and PARK15 linked FBXO7 mutations or variations are summarized in Fig. 1a.

FBXO7 proteins belongs to F-box-containing protein family (FBP) [18, 35]. These FBP proteins possess a F-box domain containing 40 amino acids [41, 42]. FBPs assist in many important cell processes such as formation of protein complexes, maintenance of genome stability, formation of synapse and circadian rhythms [41, 42]. There are three kinds of FBP proteins: FBL (FBP with F-box and leucine-rich-repeat domains), FBW (FBP with F-box and WD40 domains) and FBXO proteins (FBP with F-box domain only) [41, 42]. The FBXO7 belongs to FBXO subfamily and have 5 function domains (from N to C terminus): an UBL domain, a cdk6 domain, a dimerization domain, a F-box domain and a proline rich domain (Fig. 1) [35, 43]. WT FBXO7 proteins have two isoforms, isoform 1 has an UBL domain in its N terminus and is longer than isoform 2 (Fig. 1) [35, 43]. FBXO7 proteins are mainly expressed in cerebral cortex, globus pallidum and SN, and to a lesser extent in hippocampus and cerebellum [44]. Endogenous and overexpressed FBXO7 proteins are mostly localized to cell nucleus [36, 45]. FBXO7 proteins have been found to be positively relevant to tumorigenesis [46]. FBXO7 proteins are reported to be required for the ubiquitination and proteasome-mediated proteolysis of the hepatoma up-regulated protein (HURP), a regulator of mitotic spindle assembly [47]. In SCF^{FBXO7} complex, FBXO7 recruits HURP through its C-terminal proline-rich region in a Cdk1-cyclin B-phosphorylation dependent manner. Mutation of the multiple Cdk1-cyclin B phosphorylation sites on HURP or the proline-rich region of FBXO7 abolishes the association between FBXO7 and HURP [47]. Furthermore FBXO7 is reported to promote ubiquitination and degradation of cIAP1, an inhibitor of apoptosis family member which regulates canonical and non-canonical NF- κ B signalling [48]. Thus FBXO7 may play roles in the regulation of cIAP1 function and cell apoptosis via SCF^{FBXO7} ubiquitin E3 ligase mediated ubiquitination of cIAP1. Recently FBXO7 is found to interact




Fig. 1 Molecular structure and PD-linked generic variations of FBXO7 and Parkin. The molecular structures of FBXO7 (a) and Parkin (b) together with indications of PD-linked mutations are respectively illustrated. The detailed sites of PD-linked generic variations of frameshift or missense mutations of FBXO7 and Parkin are pointed with red or green colour arrows respectively

with PI31, a proteasome inhibitor [49]. It is found that there is a dimerization domain in both proteins, which is vital to homodimerization or heterodimerization of FBXO7 and PI31 proteins. However knockdown of FBXO7 does not affect PI31 levels, arguing against PI31 as a genuine substrate for SCF^{FBXO7} E3 ligase [49].

Recent findings demonstrate that FBXO7 is a stress responsive protein and stress of cells can up-regulate FBXO7 expression [26]. The up-regulated expression of

WT FBXO7 can protect cells against stress [26]. However PD-linked FBXO7 mutants aggravate neurotoxins induced cell demise [26]. Furthermore stress of cells can promote mitochondria translocation of FBXO7 proteins [26]. WT FBXO7 can facilitate neuroprotective mitophagy, whereas all PD-linked FBXO7 mutations inhibit mitophagy [26]. The mitophagy is an important mitochondrial quality control process and functions to selectively clear away of damaged or impaired mitochondria

by autophagy process, which was first mentioned by J.J. Lemasters in 2005 [50]. The mitophagy promotes turnover of mitochondria and prevents accumulation of dysfunctional mitochondria which can lead to neuron degeneration in PD and other human disorders [50]. It is proposed that FBXO7 may participate in mitophagy process via direct interactions with PINK1 and Parkin [51, 52]. FBXO7 may modulate the translocation of Parkin to damaged mitochondria [51]. Overexpression of WT FBXO7, but not PD-linked FBXO7 mutants, can rescue degeneration of DA neurons in Parkin null *Drosophila* [51]. These findings suggest that FBXO7 may function in a common pathway with Parkin/PINK1 protein pair to modulate mitophagy, whereas FBXO7 mutations lead to loss of these functions.

It is suggested by recent findings that WT FBXO7 protein can have dual protective as well as toxic functions [26]. Stress of cells can up-regulate FBXO7 expression to protect cells. However increased FBXO7 expression under stress can lead to formation of deleterious FBXO7 protein aggregates, especially in mitochondria [26]. PD-linked FBXO7 mutations aggravate toxic FBXO7 aggregation in mitochondria [26]. FBXO7 aggregation in mitochondria can impair mitochondria integrity, promote generation of reactive oxygen species (ROS) and finally lead to cell demise [26]. However FBXO7 aggregation induced proteotoxicity to cells can be alleviated by protein aggregation inhibitors such as L-proline, but be aggravated by prohibitin, a nature mitochondrial protease inhibitor [26]. It is proposed that FBXO7 aggregation, mitochondria impairment and ROS production may form a positive feedback loop implicated in FBXO7-linked neuron degeneration [26]. Such a situation can be aggravated by FBXO7 mutations induced mitophagy inhibition, contributing to PARK15 (Fig. 3) [26].

Parkin and Parkin-linked PARK2

Parkin mutations is a frequent cause of juvenile-onset Parkinsonism (PARK2) with onset age < 40 years [53, 54]. Parkin mutations have also been implicated in late onset PD [55]. The PARK2 gene is the first autosomal recessive Parkinsonism gene that has been mapped and cloned [13, 16]. PD-Linked Parkin mutations include deletions, multiplications and point mutations in coding regions (Fig. 1b) [56]. Parkin mutations occur in homozygotic, heterozygotic or compound heterozygotic states, mostly in ring domains of Parkin [16, 57]. Several Parkin mutations were identified in Parkin UBL domain and also in unique Parkin domain (UPD) [58, 59]. Parkin mutations induced PARK2 present with rigidity, bradykinesia, dyskinesia, postural instability and dystonia [58–60]. Post-mortem studies revealed that most PARK2 patients did not have Lewy bodies formation except in one case where Lewy bodies were present in SN and locus

coeruleus districts [61]. The other cases of PARK2 had severe loss of dopaminergic neurons in SN, Locus coeruleus, and spinocerebellar system [58, 59]. Neurofibrillary tangles can be also identified in cerebral cortex and brainstem nucleus of PARK2 patients [62, 63].

Parkin is a HECT/RING hybrid ubiquitin E3 ligase that physically receives ubiquitin on its catalytic centre and then passes them onto its substrates. The N-terminus of Parkin protein comprises of a UBL and a UPD domains (Fig. 1). The C terminus of Parkin protein consists of two RING fingers domains flanking a in-between RING (IBR) domain (Fig. 1) [57, 62]. The UBL domain is separated from UPD and RING-IBR-RING domains by a linker that comprises of cleavage sites for pro-apoptotic caspases [16, 57]. The UBL domain can bind to subunits of 19S proteasome, which is supposed to modulate proteasome function [62]. 2 RING domains interact with ubiquitin E2 co-enzymes and substrates to execute substrates ubiquitination [62]. Some studies also claim that UBL domain can also bind to substrates [64]. WT Parkin is known to promote cellular proliferation by association with several important cell cycle regulatory molecules and exhibits tumour suppressor effects [21, 56].

Parkin can recognize and interact with its specific targets, execute its E3 ligase activity to promote ubiquitination and proteasomal degradation of its substrates [65, 66]. In Parkin-linked PARK2, abnormal accumulations or deregulation of some potential deleterious Parkin substrates are supposed to be relevant to Parkin mutations induced DA neuron degeneration in PD [20]. WT Parkin, but not PD-linked Parkin mutants, can target and down regulate apoptosis inducing protein Bax to abrogate Bax-induced apoptosis [67]. Thus Parkin mutations may contribute to apoptosis via loss of control on Bax induced toxicity. The Fas-associated factor 1 (FAF1) was a positive modulator for DA neuron degeneration in PD [68]. WT Parkin, but not PD-linked mutant Parkin, can act as an E3 ubiquitin ligase to ubiquitinate and degrade FAF1, thus abrogate FAF1-mediated neuron cell demise [68]. Parkin can also target polyglutamine proteins ataxin-2 and ataxin-3 for ubiquitination to negatively control their levels and reduce these polyglutamine proteins induced cytotoxicity [69, 70]. It is found that α -Sp22 (a 22 KDa glycosylated form of α -syn) can be a substrate of Parkin [71]. However in contrast to WT Parkin, mutant Parkin failed to bind and ubiquitinate α -Sp22 leading to pathological accumulation of α -Sp22 in brain [71]. Other α -syn binding proteins including synphilin-1 and some septins are also found to be substrates of Parkin [72–76]. Co-expression of α -syn, synphilin-1 and Parkin result in the formation of Lewy-body-like ubiquitin-positive cytosolic inclusions [77]. In this case Parkin is suggested to be a dual-function

ubiquitin E3 ligase and that K63-linked ubiquitination of synphilin-1 by Parkin may be involved in the formation of Lewy body inclusions associated with PD [75]. Septins are a group of GTP-binding proteins found primarily in eukaryotic cells [78]. Septins have been implicated in the localization of cellular processes at the site of cell division, at the plasma membrane, at sites where specialized structures like cilia or flagella are attached to the cell body [79]. So far two septins (SEPT5/CDCrel-1 and SEPT4/CDCrel-2) are found to be Parkin's substrates and may potentially play roles in PD pathogenesis [56]. The SEPT4/CDCrel-2 can coaggregate with α -syn as Lewy bodies in PD, and increased level of SEPT5/CDCrel-1 can rapidly eliminate DA neurons in rat heads [75]. Thus WT Parkin may promote down regulation of SEPT4 and SEPT5 to reduce these septins induced adverse impacts on DA neuron viability. Parkin is also reported to target a putative G protein-coupled transmembrane polypeptide, named Pael receptor [80]. This receptor tends to become unfolded, insoluble, and ubiquitinated in vivo and leads to unfolded protein-induced cell death. Parkin specifically ubiquitinates this receptor and promotes the degradation of insoluble Pael receptor to suppress cell degeneration [80]. Parkin is relevant to vesicle formation [81]. The Synaptotagmin XI (important for vesicular trafficking and dynamics) is reported to be a substrate of Parkin [81]. The accumulation of Synaptotagmin XI was found in SN of PD patients [81]. Since synaptotagmin XI is a member of the synaptotagmin family that is well characterized in their importance for vesicle formation and docking, the interaction with this protein suggests a role for Parkin in the regulation of the synaptic vesicle pool and in vesicle release. Loss of Parkin could thus affect multiple proteins controlling vesicle pools, docking and release and explain the deficits in dopaminergic function seen in PD patients with Parkin mutations. Detailed Parkin substrates and their potential implications in PD pathogenesis are discussed in a well-written review paper [56].

On the other hand, Parkin can play important roles in regulating mitochondrial movement, distribution, and clearance [52, 82–86]. Parkin can cooperate with PINK1 to control mitochondria quality via modulation of mitophagy, whereas Parkin mutations impair mitophagy [52, 82, 83]. Upon mitochondria impairment, PINK1 accumulates in defective mitochondria. The accumulated PINK1 can attract Parkin from cytosol and finally cooperatively mediate clearance of damaged mitochondria via mitophagy. Indeed, activation and recruitment of Parkin onto damaged mitochondria involves PINK1-mediated phosphorylation of both Parkin and ubiquitin (Ub). Through a stepwise cascade, Parkin is converted from an autoinhibited enzyme into an active phospho-Ub-dependent E3 ligase. After activation, Parkin

can ubiquitinate itself in concert with its many mitochondrial substrates. The PINK1 induced phosphorylation of Ub conjugated to Parkin substrates can trigger further cycles of Parkin recruitment and activation. This feed-forward amplification loop regulates both Parkin activity and mitophagy. It is identified that Parkin mediates the formation of two distinct poly-ubiquitin chains, linked through Lys-63 and Lys-27 [86]. The VDAC1 (voltage-dependent anion channel 1) is recognized as a target for Parkin-mediated Lys-27 poly-ubiquitylation and subsequent mitophagy induction [86]. Besides mitofusion 1 (Mfn1) and mitofusion 2 (Mfn2), large GTPases that mediate mitochondrial fusion, can be substrates of Parkin for mitophagy induction [84]. Parkin is also found to modulate autophagy and mitophagy via mono-ubiquitination of Bcl-2 [87]. Furthermore PINK1 and Parkin are also reported to play role in arresting mitochondrial movement via targeting Miro, a component of the primary motor/adaptor complex that anchors kinesin to the mitochondrial surface [88]. PINK1 phosphorylates Miro and phosphorylation of Miro activates proteasomal degradation of Miro in a Parkin-dependent manner [88]. Removal of Miro from mitochondrion also detaches kinesin from its surface [88]. Thus by preventing mitochondrial movement, the PINK1/Parkin pathway may quarantine damaged mitochondria prior to their clearance via mitophagy [88]. The mitochondrial dynamin related protein-1 (Drp1) can also be the target of Parkin [85]. WT Parkin interacts with and subsequently ubiquitinates Drp1 to promote its proteasome-dependent degradation [85]. Pathogenic mutant Parkin inhibits the ubiquitination and degradation of Drp1, leading to an increased level of Drp1 for mitochondrial fragmentation and cell viability impairment [85].

Clinical aspects of Parkin and FBXO7 linked PD carriers

Homozygous or heterozygous mutations in Parkin and FBXO7 are both associated with early onset autosomal recessive Parkinsonism (PARK2 and PARK15). The common clinical features of PARK2 and PARK15 include classic PD symptoms including rigidity, bradykinesia and postural instability [89, 90]. In addition they have atypical features such as hyperreflexia, foot dystonia, sleep benefit, diurnal fluctuations and early susceptibility to levodopa induced dyskinesia [91]. Compared with PARK2, the FBXO7-linked PARK15 progress more rapidly and is more severe. In PARK 15, Parkinsonism can be accompanied with signs of cognitive decline, loss of sustained levodopa responsiveness, severe levodopa induced bradykinesia as well as pyramidal signs such as hyperreflexia and babinski signs [15, 17]. PARK15 carriers also exhibit other signs such as eyelid aphasia, slow saccade and early imbalance in posture [92]. However resting tremor is not a common feature of PARK 15

[44]. We have analyzed and summarized the onset age of PARK2 and PARK15 based on published reports [17, 18, 20–22, 51, 52, 54, 57, 58, 74–76, 78, 89]. About 38 cases of PARK2 and 9 cases of PARK15 patients with detailed onset ages were analyzed (Table 1). After ANOVA statistic analysis, we find that PARK15 has significant earlier PD onset age than PARK2 (Table 1). Furthermore it appears that PARK15 has a wider and more complicated network of neuronal degeneration than PARK2 [36, 44].

Pathophysiologic aspects of Parkin and FBXO7 linked PD

There are overlapping and divergent pathophysiological roles between Parkin and FBXO7. The physiological roles of Parkin and FBXO7 are summarized in Fig. 2. Both Parkin and FBXO7 play a common role in UPS [35, 67, 98]. The Parkin is a HECT/RING hybrid ligase, whereas FBXO7 is an adaptor protein in Skp-Cullin-F-box (SCF) SCF^{FBXO7} ubiquitin E3 ligase complex [12, 43]. Parkin and FBXO7 are both implicated in tumorigenesis [51]. WT Parkin and FBXO7 can both be cytoprotective, whereas their PD-linked mutants are all deleterious to DA neurons. Both WT Parkin and FBXO7 promote mitophagy, whereas their PD-linked mutants impair mitophagy. Furthermore FBXO7 and Parkin have reciprocal interactions, suggesting overlaps of their signaling pathways. WT FBXO7 but not PD-linked FBXO7 mutants can rescue lack of Parkin induced PD symptoms in flies [51]. FBXO7 was reported to mediate mitochondria translocation of Parkin [51]. Therefore FBXO7 may act upstream of Parkin and have Parkin independent complicated functions. Our recently findings show that FBXO7 proteins can form deleterious aggregates in mitochondria [26]. However no reports have shown that Parkin can form protein aggregates in mitochondria. The similarities and differences of their pathophysiological roles are summarized in Table 2.

Conclusions

Mutations of Parkin and FBXO7, two proteins in UPS, are both implicated in pathogenesis of early onset DA neuron degeneration in PD (PARK2 and PARK15). Both WT Parkin and FBXO7 can facilitate, but their PD-linked mutants impair neuroprotective mitophagy. However WT FBXO7 can have dual protective or deleterious functions. FBXO7 proteins, especially PD-linked FBXO7 mutants, can form deleterious protein aggregates in mitochondria under stress, leading to proteotoxic stress in mitochondria. Taken together, FBXO7 mutations may lead to neurodegeneration via impairment of UPS, inhibition of mitophagy and formation of deleterious FBXO7 aggregates. On the other hand Parkin mutations may induce neuron degeneration via impairment of UPS together with inhibition of mitophagy (Fig. 3). The

Table 1 Onset ages of PARK2 and PARK15

PARK2 [15, 55, 58, 94–97]		PARK15 [17, 18, 44, 45, 92]	
Case no	Ages	Case no	Ages
1	7	1	10
2	10	2	13
3	13	3	17
4	13	4	17
5	13	5	18
6	15	6	19
7	15	7	20
8	16	8	22
9	18	9	24
10	18		
11	19		
12	20		
13	20		
14	22		
15	23		
16	24		
17	26		
18	27		
19	28		
20	28		
21	28		
22	28		
23	29		
24	29		
25	29		
26	30		
27	30		
28	31		
29	32		
30	33		
31	34		
32	34		
33	45		
34	45		
35	47		
36	54		
37	61		
38	65		
Average ± SD	27.87 ± 13.37	17.78 ± 4.3*	

**P* = 0.032




Fig. 2 Physiological roles of FBXO7 and Parkin in UPS. **a**, the physiological roles of FBXO7 in SCF^{FBXO7} E3 ligase complex. FBXO7 acts as an adaptor protein to recognize and interact with its substrates for SCF^{FBXO7} E3 ligase mediated ubiquitination. After interaction with its substrates, FBXO7 will bind with SKP1 which further interact with Cul1 and ROC1 to form functional SCF^{FBXO7} E3 ligase complex. The SCF^{FBXO7} E3 ligase will mediate E2 ligase induced ubiquitination of FBXO7 substrates. **b**, the physiological roles of Parkin. After interaction with its substrates, Parkin exerts its E3 ligase activity to mediate ubiquitination of its substrates by E2 ligase. **c**, detailed procedures of SCF^{FBXO7} and Parkin E3 ligases mediated ubiquitination and proteasome degradation of substrates. (Left), SCF^{FBXO7} E3 ligase mediated substrates recognition, ubiquitination and proteasomal degradation. (Right), Parkin mediated substrates recognition, ubiquitination and proteasomal degradation

Table 2 Comparison of physiological and pathological features of FBXO7 and Parkin

	FBXO7 ^[18, 26, 34, 36, 51]	Parkin ^[26, 28, 52, 56, 65, 83]
Pathway involved	UPS	UPS
Function in pathway	adaptor protein in SCF E3 complex	E3 ligase
Subcellular localization		
nucleus localization	++	+
cytosol localization	+	++
mitochondria localization	+	+/-
	++	+
Mitophagy modulation		
WT	↑↑	↑
Mutants	↓	↓
Aggregates formation		
WT	++	+
Mutants	+++	++
Stress induction	++	+
Aggregates in mitochondria		
WT	+	-
Mutants	++	-
Impact on mitochondrial function		
WT	↑↓	↑
Mutants	↓↓	↓
Neuroprotection of WT protein	+	+
Location in Lewy body	+	+/-
Implicated in oncogenesis	+	+
Implicated in other human neurodegenerative disease	+	-

UPS, ubiquitin-proteasome system; SCF, Skp-cullin-F-box protein complex;


pathophysiologic variances between FBXO7 and Parkin can partially account for different clinical phenotypes of PARK15 and PARK2 (Fig. 3). Further studies are needed to unravel the common pathophysiologic links between these two proteins with the hope to identify specific pathways for targeted therapy in PD.

Ethics approval

Not applicable, as no human subjects have been directly involved.

Availability of data and materials

Not applicable, as no original data has been used in the current review manuscript.



Abbreviations

AD: Alzheimer's disease; CDCrel: cell division control related protein; DA: dopamine; Drp1: dynamin related protein-1; FAF1: Fas-associated factor 1; FBP: F-box-containing protein; FBXO7: F-box protein 7; FPD: familial form Parkinson's disease; HSP90: heat shock protein 90; IBR: in-between RING domain; LRRK2: Leucine rich repeat kinase 2; mtUPR: mitochondria unfold protein response; PD: Parkinson's disease; ROS: reactive oxygen species; SCF: Skp-Cullin-F-box E3 ligase complex; SN: substantia nigra pars compacta; SPD: sporadic Parkinson's disease; UBL domain: ubiquitin like domain; UPD: unique Parkin domain; UPS: ubiquitin proteasome system; WT: wild type; α -syn: α -synuclein.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

ZZD and SS contributed to manuscript composition as well as construction of figures and tables. ADC provided constructive suggestions and comments to improve the manuscript. TEK performed final manuscript revising and touching up. All authors read and approved the final manuscript.

Acknowledgment

We thank Singapore National Medical Research Council (STaR and Transition awards, and clinical translational research programme in Parkinson's disease) for their support.

Funding

This study is supported by Singapore National Medical Research Council (NMRC) grants including STaR and Transition awards, and clinical translational research programme in Parkinson's disease.

Author details

¹National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore. ²Department of Neurology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore. ³Signature Research Program in Neuroscience and Behavioural Disorders, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857, Singapore.

Received: 9 February 2016 Accepted: 6 April 2016

Published online: 18 April 2016

References

- Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AHV, Halliday G. Missing pieces in the Parkinson's disease puzzle. *Nat Med*. 2010;16:653–61.
- Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. *Hum Mutat*. 2007;28(7):641–53.
- Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Parkinson's disease. *Parkinsonism Relat Disord*. 2012;18:S183–5.
- Davie CA. A review of Parkinson's disease. *Br Med Bull*. 2008;86:109–27.
- Petit GH, Olsson TT, Brundin P. The future of cell therapies and brain repair: Parkinson's disease leads the way. *Neuropathol Appl Neurobiol*. 2014;40:60–70.
- Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. *EMBO J*. 2008;27:336–49.
- Kasten M, Klein C. The many faces of alpha-synuclein mutations. *Mov Disord*. 2013;28:697–701.
- Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. *Nat Rev Neurosci*. 2002;3:932–42.
- Uversky VN, Eliezer D. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. *Curr Protein Pept Sci*. 2009;10:483–99.

10. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. *Neuron*. 2003;39:889–909.
11. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. *Neuron*. 2003;39:889–909.
12. Li H, Guo M. Protein degradation in Parkinson disease revisited: it's complex. *J Clin Invest*. 2009;119:442–5.
13. Hattori N, Shimura H, Kubo S, Kitada T, Wang M, Asakawa S, Minashima S, Shimizu N, Suzuki T, Tanaka K, Mizuno Y. Autosomal recessive juvenile parkinsonism: a key to understanding nigral degeneration in sporadic Parkinson's disease. *Neuropathology*. 2000;20(Suppl):85–90.
14. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. *Neuron*. 2010;66:646–61.
15. Bonifati V. Autosomal recessive parkinsonism. *Parkinsonism & Related Disorders* 2012;(Suppl 1):S4–S6.
16. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. 1998;392:605–8.
17. Di Fonzo A, Dekker MCJ, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LOM, Wouters CH, de Graaff E, Oyen WJG, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. *Neurology*. 2009;72:240–5.
18. Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. *JAMA Neurol*. 2013;70:20–4.
19. Tuoc TC, Stoykova A. Roles of the ubiquitin-proteasome system in neurogenesis. *Cell Cycle*. 2010;9:3174–80.
20. Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. *Biochim Biophys Acta*. 2009;1792(7):664–75.
21. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: Curse or blessing. *Acta Neuropathol*. 2012;124(2):153–172.
22. Cohen E, Dillin A. The insulin paradox: aging, proteotoxicity and neurodegeneration. *Nat Rev Neurosci*. 2008;9:759–67.
23. Willis M, Patterson C. Proteotoxicity and Cardiac Dysfunction — Alzheimer's Disease of the Heart? *N Engl J Med*. 2013;368:455–64.
24. Douglas PM, Summers DW, Cyr DM. Molecular chaperones antagonize proteotoxicity by differentially modulating protein aggregation pathways. *Prion*. 2009;3:51–8.
25. Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. *J Cell Biol*. 2010;190(5):719–29.
26. Zhou ZD, Xie SP, Sathiyamoorthy S, Saw WT, Ye T, Ng SH, Pek H, Chua H, Mei A, Tang Y, Shaffra F. F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy. *Hum Mol Genet*. 2015;24(22):1–59.
27. Giasson BI, Lee VMY. Are ubiquitination pathways central to Parkinson's disease? *Cell*. 2003;114(1):1–8.
28. Martins-Branco D, Esteves AR, Santos D, Arduino DM, Swerdlow RH, Oliveira CR, Januario C, Cardoso SM. Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness? *Exp Neurol*. 2012;238:89–99.
29. Lim K-L, Tan JMM. Role of the ubiquitin proteasome system in Parkinson's disease. *BMC Biochem*. 2007;8 Suppl 1:S13.
30. Zhou Z, Kerk S, Meng Lim T. Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132. *Free Radic Res*. 2008;42:456–66.
31. Zhou ZD, Lim TM. Dopamine (DA) induced irreversible proteasome inhibition via DA derived quinones. *Free Radic Res*. 2009;43:417–30.
32. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. *Nat Med*. 2005;11:1214–21.
33. Shojaei S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi G-A, Fakhrai-Rad H, Ronaghi M, Elahi E. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. *Am J Hum Genet*. 2008;82:1375–84.
34. Politis AM, Kokras N, Pappa D, Siarkos C, Katirtzoglou E, Papadimitriou GN, Kahn DA. A severe and irreversible case of tardive rigid-akinetic parkinsonian syndrome: the role of the DaTscan. *J Psychiatr Pract*. 2013;19:413–8.
35. Larsen K, Bendixen C. Characterization of the porcine FBXO7 gene: The first step towards generation of a pig model for Parkinsonian pyramidal syndrome. *Mol Biol Rep*. 2012;39:1517–26.
36. Zhao T, de Graaff E, Breedveld GJ, Loda A, Severijnen LA, Wouters CH, Verheijen FW, Dekker MCJ, Montagna P, Willemsen R, Oostra BA, Bonifati V. Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). *PLoS One*. 2011;6:e16983.
37. Lohmann E, Coquel A-S, Honoré A, Gurvit H, Hanagasi H, Emre M, Leutenegger AL, Drouet V, Sahbatou M, Guven G, Erginel-Unaltuna N, Deleuze J-F, Lesage S, Brice A. A new F-box protein 7 gene mutation causing typical Parkinson's disease. *Mov Disord*. 2015;30:1130–3.
38. Nelson DE, Randle SJ, Laman H. Beyond ubiquitination: the atypical functions of Fbxo7 and other F-box proteins. *Open Biol*. 2013;3:130131.
39. Santoro L, Breedveld GJ, Manganello F, Iodice R, Pisciotto C, Nolano M, Punzo F, Quarantelli M, Pappata S, Di Fonzo A, Oostra BA, Bonifati V. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. *Neurogenetics*. 2011;12:33–9.
40. Chen C-M, Chen I-C, Huang Y-C, Juan H-F, Chen Y-L, Chen Y-C, Lin C-H, Lee L-C, Lee C-M, Lee-Chen G-J, Lai Y-J, Wu Y-R. FBXO7 Y52C Polymorphism as a Potential Protective Factor in Parkinson's Disease. *PLoS One*. 2014;9:e101392.
41. Kipreos ET, Pagano M. The F-box protein family. *Genome Biol*. 2000;1:REVIEWS3002.
42. Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. *Nat Rev Mol Cell Biol*. 2013;14:369–81.
43. Ho MS, Tsai PI, Chien CT. F-box proteins: The key to protein degradation. *J Biomed Sci*. 2006;13(2):181–91.
44. Paísán-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingsenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H. Early-onset L-dopa-responsive Parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and Spatacsin mutations. *Movement Disorders*. 2010;25(12):1791–800.
45. Zhao T, Severijnen L-A, van der Weiden M, Zheng P, Oostra B, Hukema R, Willemsen R, Kros J, Md P, Bonifati V. FBXO7 Immunoreactivity in [alpha]-Synuclein-Containing Inclusions in Parkinson Disease and Multiple System Atrophy. *J Neuropathol Exp Neurol*. 2013;72:482–8.
46. Laman H, Funes JM, Ye H, Henderson S, Galinanes-Garcia L, Hara E, Knowles P, McDonald N, Boshoff C. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6. *EMBO J*. 2005;24:3104–16.
47. Hsu JM, Lee YCG, Yu CTM, Huang CYF. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region. *J Biol Chem*. 2004;279:32592–602.
48. Chang YF, Cheng CM, Chang LK, Jong YJ, Yuo CY. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. *Biochem Biophys Res Commun*. 2006;342:1022–6.
49. Kirk R, Laman H, Knowles PP, Murray-Rust J, Lomonosov M, Meziane EK, McDonald NQ. Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. *J Biol Chem*. 2008;283:22325–35.
50. Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. *Rejuvenation Res*. 2005;8:3–5.
51. Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM, Pogson JH, Randle SJ, Wray S, Lewis PA, Houlden H, Abramov AY, Hardy J, Wood NW, Whitworth AJ, Laman H, Plun-Favreau H. The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. *Nat Neurosci*. 2013;16:1257–65.
52. Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ, Pallanck LJ. The PINK1-Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. *Proc Natl Acad Sci U S A*. 2013;110:6400–5.
53. Lücking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denèfle P, Wood NW, Agid Y, Brice A. Association between early-onset Parkinson's disease and mutations in the parkin gene. *N Engl J Med*. 2000;342:1560–7.
54. West A, Periquet M, Lincoln S, Lücking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Deleuze JF, Maraganore D, Levey A, Wood N, Dürr A, Hardy J, Brice A, Farrer M. Complex relationship between Parkin mutations and Parkinson disease. *Am J Med Genet - Neuropsychiatr Genet*. 2002;114:584–91.
55. Bilgic B, Bayram A, Arslan AB, Hanagasi H, Dursun B, Gurvit H, Emre M, Lohmann E. Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: Contribution of automated segmentation neuroimaging method. *Park Relat Disord*. 2012;18:562–6.
56. Sandebring A, Cedazo-Minguez A. Parkin- An E3 Ubiquitin Ligase with Multiple Substrates. *J Alzheimers Dis Park*. 2012;5:101–6.

57. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CD98. *Proc Natl Acad Sci U S A*. 2000;97:13354–9.
58. Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, Bhatia KP, Quinn N. Parkin disease: A phenotypic study of a large case series. *Brain*. 2003;126:1279–92.
59. Fiala O, Pospisilova L, Prochazkova J, Matejckova M, Martasek P, Novakova L, Roth J, Ruzicka E. Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson's disease. *Neuroendocrinol Lett*. 2010;31:187–92.
60. Corti O, Lesage S, Brice A. What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease. *Physiol Rev*. 2011;91:1161–218.
61. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW. Lewy bodies and parkinsonism in families with parkin mutations. *Ann Neurol*. 2001;50:293–300.
62. Kahle PJ, Haass C. How does parkin ligate ubiquitin to Parkinson's disease? *EMBO Rep*. 2004;5:681–5.
63. Angeles DC, Ho P, Chua LL, Wang C, Yap YW, Ng C, Zhou ZD, Lim K-L, Wszolek ZK, Wang HY, Tan EK. Thiol-peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in *Drosophila*. *Hum Mol Genet*. 2014;23(12):3157–65.
64. Caughey B, Raymond GJ, Priola SA, Kocisko DA, Race RE, Bessen RA, Lansbury PT, Chesebro B. Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update *Mol Biotechnol*. 1999;13:45–55.
65. Trempe J-F, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, Al-Abdul-Wahid S, Krett J, Wong K, Kozlov G, Nagar B, Fon EA, Gehring K. Structure of parkin reveals mechanisms for ubiquitin ligase activation. *Science*. 2013;340:1451–5.
66. Riley BE, Loughheed JC, Callaway K, Velasquez M, Brecht E, Nguyen L, Shaler T, Walker D, Yang Y, Regnstrom K, Diep L, Zhang Z, Chiou S, Bova M, Artis DR, Yao N, Baker J, Yednock T, Johnston JA. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. *Nat Commun*. 2013;4(May):1982.
67. Johnson BN, Bergera K, Cortese GP, LaVoie MJ. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. *Proc Natl Acad Sci*. 2012;109:6283–8.
68. Sul JW, Park MY, Shin J, Kim YR, Yoo SE, Kong YY, Kwon KS, Lee YH, Kim E. Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration. *Hum Mol Genet*. 2013;22:1558–73.
69. Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. *J Biol Chem*. 2003;278:22044–55.
70. Huynh DP, Nguyen DT, Pulst-Korenberg JB, Brice A, Pulst SM. Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. *Exp Neurol*. 2007;203:531–41.
71. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. *Science*. 2001;293:263–9.
72. Yang H, Zhou H-Y, Li B, Chen S-D. Neuroprotection of Parkin against apoptosis is independent of inclusion body formation. *Neuroreport*. 2005;16:1117–21.
73. Lim KL, Chew KCM, Tan JMM, Wang C, Chung KKK, Zhang Y, Tanaka Y, Smith W, Engelender S, Ross CA, Dawson VL, Dawson TM. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. *J Neurosci*. 2005;25:2002–9.
74. Volles MJ, Lansbury PT. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. *J Mol Biol*. 2007;366:1510–22.
75. Ageta-Ishihara N, Yamakado H, Morita T, Hattori S, Takao K, Miyakawa T, Takahashi R, Kinoshita M. Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice. *Mol Brain*. 2013;6:35.
76. Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim SY, Dawson TM, Zhang H, Sulzer D, Yang L, Beal MF, Degiorgio LA, Chun HS, Baker H, Peng C. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. *J Neurochem*. 2005;94:1040–53.
77. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. *Nat Med*. 2001;7:1144–50.
78. Weirich CS, Erzberger JP, Barral Y. The septin family of GTPases: architecture and dynamics. *Nat Rev Mol Cell Biol*. 2008;9:478–89.
79. Mostowy S, Cossart P. Septins: the fourth component of the cytoskeleton. *Nat Rev Mol Cell Biol*. 2012;13:183–94.
80. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress. Is a Substrate of Parkin. 2001;105:891–902.
81. Huynh DP, Scoles DR, Nguyen D, Pulst SM. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. *Hum Mol Genet*. 2003;12:2587–97.
82. Glauser L, Sonnay S, Stafa K, Moore DJ. Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. *J Neurochem*. 2011;118:636–45.
83. Kazlauskaitė A, Kondapalli C, Goulay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MMK. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. *Biochem J*. 2014;460:127–39.
84. Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M, Youle RJ. Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. *J Cell Biol*. 2010;191:1367–80.
85. Wang H, Song P, Du L, Tian W, Yue W, Liu M, Li D, Wang B, Zhu Y, Cao C, Zhou J, Chen Q. Parkin ubiquitinates Drp1 for proteasome-dependent degradation: Implication of dysregulated mitochondrial dynamics in Parkinson disease. *J Biol Chem*. 2011;286:11649–58.
86. Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol*. 2010;12:119–31.
87. Chen D, Gao F, Li B, Wang H, Xu Y, Zhu C, Wang G. Parkin mono-ubiquitinates Bcl-2 and regulates autophagy. *J Biol Chem*. 2010;285:38214–23.
88. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, Lavoie MJ, Schwarz TL. PINK1 and Parkin target miro for phosphorylation and degradation to arrest mitochondrial motility. *Cell*. 2011;147:893–906.
89. Nagatsua T, Sawadab M. L-dopa therapy for Parkinson's disease: past, present, and future. *Parkinsonism Relat Disord*. 2009;15 Suppl 1:S3–8.
90. Mouradian MM, Heuser IJ, Baronti F, Fabbri G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. *Ann Neurol*. 1989;25:523–6.
91. Lin CH, Chen ML, Lai TT, Tai CH, Wu RM. Mutational analysis of FBXO7 gene in Parkinson's disease in a Taiwanese population. *Neurobiol Aging*. 2013;34:1713.e1–4.
92. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. *Arch Neurol*. 2010;67:731–8.
93. Klein C, Djarmati A, Hedrich K, Schäfer N, Scaglione C, Marchese R, Kock N, Schüle B, Hiller A, Lohnau T, Winkler S, Wieggers K, Hering R, Bauer P, Riess O, Abbruzzese G, Martinelli P, Pramstaller PP. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. *Eur J Hum Genet*. 2005;13:1086–93.
94. Padmaja MV, Jayaraman M, Srinivasan AV, Srisailapathy CRS, Ramesh A. PARK2 gene mutations in early onset Parkinson's disease patients of South India. *Neurosci Lett*. 2012;523:145–7.
95. Chan DKY, Mok V, Ng PW, Yeung J, Kwok JB, Fang ZM, Clarke R, Wong L, Schofield PR, Hattori N. PARK2 mutations and clinical features in a Chinese population with early-onset Parkinson's disease. *J Neural Transm*. 2008;115:715–9.
96. Bonifati V, De Michele G, Lücking CB, Dürr A, Fabrizio E, Ambrosio G, Vanacore N, De Mari M, Marconi R, Capus L, Breteler MM, Gasser T, Oostra B, Wood N, Agid Y, Filla A, Meo G, Brice A. The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. *Neurol Sci*. 2001;22:51–2.
97. Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Case-control study of the parkin gene in early-onset Parkinson disease. *Arch Neurol*. 2006;63:548–52.
98. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RLJ, Hess S, Chan DC. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum Mol Genet*. 2011;20:1726–37.